CAS 138783-13-8
:Biciromab
Description:
Biciromab, with the CAS number 138783-13-8, is a monoclonal antibody that has been developed for therapeutic applications, particularly in the field of oncology. It is designed to target specific antigens on cancer cells, thereby facilitating the immune system's ability to recognize and destroy these cells. The structure of Biciromab consists of a variable region that binds to the target antigen and a constant region that mediates immune effector functions. Its mechanism of action typically involves the recruitment of immune cells to the tumor site, enhancing the immune response against the cancer. Biciromab may also exhibit properties such as high specificity and affinity for its target, which are crucial for minimizing off-target effects and maximizing therapeutic efficacy. As with many monoclonal antibodies, its pharmacokinetics can be influenced by factors such as the patient's immune response and the presence of other medications. Clinical studies are essential to determine its safety, efficacy, and potential side effects in patients.
Formula:Unspecified
Synonyms:- Biciromab
- Fibriscint
- Immunoglobulin G, anti-(human fibrin II β-chain) Fab' fragment (mouse monoclonal T2G1s γ-chain), disulfide with mouse monoclonal T2G1s light chain
- Immunoglobulin G (mouse monoclonal T2G1s Fab' fragment anti-human fibrin II β-chain), disulfide with mouse monoclonal T2G1s light chain
- T 2G1s
Sort by
The purity filter is not visible because current products do not have associated purity data for filtering.
Found 1 products.
